D.E. Shaw & Co
AVLN

D.E. Shaw & Co’s Avalyn Pharma AVLN Stock Holding History

D.E. Shaw & Co’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Buy
+23,000
New +$664K ﹤0.01% 3942

Other funds holding AVLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co's AVLN Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 23,000 shares worth $757K. The stake represents ﹤0.01% of the portfolio and ranks #3942 among its holdings.

92 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • D.E. Shaw & Co held 23,000 shares of Avalyn Pharma worth $757K as of Q2 2026.
  • Avalyn Pharma was a new D.E. Shaw & Co position in Q2 2026.
  • Avalyn Pharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3942 holding.
  • 92 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.